Metagenomi Therapeutics (MGX) Return on Sales (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Return on Sales data on file, last reported at 0.18% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.18%, down 12.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04% (down 2.0% YoY), and the FY2025 annual result was 0.03%, down 2.0% from the prior year.
• Return on Sales declined to 0.18% in Q1 2026 per MGX's latest filing, from 0.06% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q2 2024 and troughed at 0.18% in Q1 2026.
• A 4-year average of 0.04% and a median of 0.02% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2024 and 2026: Return on Sales rose 1 bps in 2024, then decreased 12 bps in 2026.
• A 4-year view of Return on Sales shows it stood at 0.02% in 2023, then plunged by 56 bps to 0.02% in 2024, then plunged by 137 bps to 0.06% in 2025, then plunged by 221 bps to 0.18% in 2026.
• Business Quant data shows MGX's Return on Sales at 0.18% in Q1 2026, 0.06% in Q4 2025, and 0.02% in Q3 2025.